BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.
Also called NCT00910065
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 270 participants
- Sponsor
- Registry
-
NCT00910065 -
2007-005163-94
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China, Germany, Russia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT00910065. Randomized; no masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2014-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
- Acronym
- ACUTE
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV
- Intervention (Drug)
- D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV
- Intervention (Drug)
- Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct00910065- Content hash
161ee5e13f0276bbb3a0fd03479b28d8794872a0c4380f30fb24fd8a02880410